3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
178
Lung Neoplasms
56
NSCLC
11
Neoplasms
10
Neoplasm Metastasis
9
Brain Neoplasms
8
Carcinoma
7
Bronchial Neoplasms
5
Thoracic Neoplasms
4
Colorectal Neoplasms
4
Respiratory Tract Neoplasms
3
Respiratory Tract Diseases
3
Neoplasms by Site
3
Meningeal Carcinomatosis
3
Lung Diseases
3
Carcinoma, Squamous Cell
3
Breast Neoplasms
3
Adenocarcinoma of Lung
3
Adenocarcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Noonan Syndrome
2
Non Small Cell Lung Cancer Metastatic
2
Neoplasms, Nerve Tissue
2
Neoplasms by Histologic Type
2
Carcinoma, Bronchogenic
2
Triple Negative Breast Neoplasms
1
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
osimertinib
×
Thoracic
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA